Voyager Therapeutics (VYGR) Tops Q4 EPS by 154c

Voyager Therapeutics (NASDAQ: VYGR) reported Q4 EPS of $1.25, $1.54 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $90.06 million versus the consensus estimate of $20.63 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Darden Restaurants (DRI) PT Raised to $240 at UBS as Stock Remains a 'Quality Compounder'
• KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty